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To date, the treatment of immune-mediated kidney diseases has only marginally beneﬁted from highly
speciﬁc biological drugs that have demonstrated remarkable effects in many other diseases. What ac-
counts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on
Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the
translational ﬂow of target identiﬁcation, and preclinical and clinical target validation in the domain of
immune-mediated kidney disease. A broad panel of experts including basic scientists, translational
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researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the Amer-
ican and European regulatory authorities made recommendations on how to overcome such hurdles at all
levels of the translational research process. The results of these discussions are presented here, which
may serve as a roadmap for how to optimize the process of developing more innovative and effective
drugs for patients with immune-mediated kidney diseases.
Kidney Int Rep (2016) 1, 327–339; http://dx.doi.org/10.1016/j.ekir.2016.06.009
KEYWORDS: autoimmunity; inﬂammation; lupus; rejection; stem cells; vasculitis
ª 2016 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
D uring the last decade, a plethora of novel anti-inﬂammatory and immunomodulatory drugs have
been developed and demonstrated to have profound
efﬁcacy with diminished toxicity in inﬂammatory and
autoimmune diseases of several medical specialties,
including rheumatology, dermatology, and immu-
nology.1 Nephrology has not yet signiﬁcantly beneﬁted
from these innovations. Belatacept, a selective T-cell cos-
timulation blocker, indicated for prophylaxis of kidney
transplant rejection; rituximab (RTX), a CD20-directed
cytolytic antibody, indicated for the treatment of anti-
neutrophil cytoplasmic autoantibody (ANCA)-associated
vasculitis; and eculizumab, a complement inhibitor,
indicated for the treatment of atypical hemolytic uremic
syndrome to inhibit complement-mediated thrombotic
microangiopathy, remain, so far, the only signiﬁcant
US Food and Drug Administration-approved innovative
treatments in nephrology. Many other promising drugs
to reset immune tolerance and suppress inﬂammation
failed to demonstrate efﬁcacy in multicenter randomized
controlled trials (RCTs). In particular, lupus nephritis has
turned out to be a challenging area for drug innovations.
Signiﬁcant and cumulative concerns about concep-
tual hurdles in current translational kidney disease
research2 (Table 1) prompted the International Society of
Nephrology to organize a global Nexus meeting on the
topic of “Translational Immunology in Nephrology,”
which was held in Berlin, Germany, from 14 to 17 April
2016. During this meeting, experts and participants
from basic science, clinical science, pharmaceutical in-
dustry, and regulatory bodies deﬁned problems and
discussed potential solutions (Figure 1).
This report summarizes the results of the meeting
and provides the framework for coordinating further
efforts to overcome existing hurdles and to improve the
translational ﬂow of target identiﬁcation, validation,
and eventually innovative drug approval for immune-
mediated kidney diseases.
Three speakers from the meeting are featured in
PowerPoint presentationswith audio linked to this paper.
Dr.AdeeraLevindiscusses translational immunology;Dr.
Giuseppe Remuzzi explains how to set up a translational
kidney research program; and Dr. Paul Brunetta covers
the topic of biological drugs from bench to bedside.
Challenges
Global View
The global challenges in nephrology are surprisingly
similar in different parts of the world. The prevalence
of chronic kidney disease (CKD) and end-stage renal
disease (ESRD) is increasing in developed and devel-
oping countries, because of increasing lifespan and
skyrocketing rates of obesity, diabetes, and hyperten-
sion.3,4 Developing countries also face additional in-
fectious and toxic triggers of kidney disease.5 In
developing countries with limited or no access to renal
replacement therapy (RRT), ESRD can only be avoided
by preventing CKD progression.6 In countries with
Table 1. Current challenges
 Prevention of chronic kidney disease (CKD) and CKD progression to end-stage renal
disease (ESRD) in a global unmet medical need with little awareness in public,
academia, and industry.
 In developed countries, the current focus on renal replacement therapy (RRT) (dialysis
and transplantation) shifts awareness from ESRD prevention toward care. Most
nephrology units are maintained from RRT-related incomes. Little or no ﬁnancial
incentives are put on prevention of ESRD, although preventing ESRD would be cost-
effective for health care systems.
 In disciplines such as oncology, dermatology, and rheumatology, the ﬁnancial
incentives, public interest, and research activities are exclusively focused on prevention
of (organ) failure. These disciplines enjoy increasing popularity among young doctors,
industry investments, and new drug approvals, whereas nephrology is currently one of
the least attractive medical subjects among younger residents.
 Basic kidney research is strong but largely disconnected from clinical research. The
translational ﬂow is poor.
 Animal models may mimic human disease by histological lesion but rarely by
pathomechanism. Animal data poorly predict clinical trial outcomes.
 At times where other ﬁelds establish personalized and precision medicine kidney
disease entities remain largely categorized based on histopathological lesions or a
combination of unspeciﬁc biomarkers that do not allow stratifying patients to treatments
that target speciﬁc pathological mechanisms.
 Immune-mediated kidney diseases are mostly rare diseases but few multinational trial
networks exist to conduct meaningful randomized controlled trials.
 There is a paucity of national registries and open access databases on the
epidemiology, phenotype, and renal care data of kidney disease patients.
 No consistent workup on race/ethnicity differences of disease phenotypes,
pharmacogenetics, and treatment outcomes.
 Genetic basis of adult kidney disease largely unexplored.
 Nephron number is a critical determinant of renal prognosis, but no biomarker of
nephron number is available and little efforts are underway. Nephrology (and trial
endpoint criteria) remains largely based on the 2 biomarkers serum creatinine and
proteinuria, which often implies a late CKD diagnosis and a small window of
opportunity for preventing ESRD.
 Trials in immune-mediated kidney diseases are often set up as superiority trials, which
put a barrier to novel immunosuppressant drugs with overlapping mechanisms of
action to intense standard immunosuppression.
 Regulatory hurdles put high barriers for investigator-initiated trials, making it very hard
to fulﬁll all requirements for academic initiatives devoid of industrial funding.
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unlimited access to RRT, the majority of renal care
providers are engaged in RRT, which together with the
renal replacement industry has shifted academic
research activities away from CKD prevention.
Although programs in CKD/ESRD prevention are likely
to be highly cost-effective for national health care
systems all over the world, minimal coordinated efforts
are made by public bodies, academia, industry, and
society. The reasons for this lack of awareness at all
levels are the asymptomatic nature of CKD, a general-
ized complacency because we have RRT and can often
avoid death from renal failure, and the ﬁnancial in-
centives of providing RRT. Although RRT catapulted
nephrology to among the most attractive medical spe-
cialties some decades ago, the situation has dramatically
changed in the recent years. The development of
innovative drugs that promise cures for disease is
currently revolutionizing many other medical spe-
cialties such as oncology, dermatology, and rheuma-
tology, thereby attracting the attention of
pharmaceutical companies, physicians in training, and
medical students. Indeed, nephrology is no longer
considered an attractive career option among medical
residents.7,8
Awareness
The enormous unmet medical need for the prevention of
ESRD requires deﬁning suitable interventions. These
can include awareness campaigns such as the World
Kidney Day or smart phone apps to alert patients to take
medications, make doctor appointments, and access lab
results. Awareness is needed concerning the importance
ofmaintaining an adequate nephron number throughout
life, primary preventive measures such as avoidance of
nephrotoxic drugs, control of hypertension, and control
of diabetes, and secondary prophylaxis in those with
nephron loss due to a previous acute kidney injury (AKI)
episode or age-related nephropathy, which is relevant to
large segments of the elderly population.
Oversimpliﬁcation
Although such preventive measures may ultimately
save more people from reaching ESRD, industry and
academic researchers remain largely focused on drug-
gable interventions for patients who already have kid-
ney disease that is often well advanced. However,
kidney disease categories are currently largely over-
simpliﬁed. Although the community seeks cures for
“AKI” and “CKD,” the concept of “nephron loss over
a lifetime” might be more useful to appreciate the
accumulating risk of ESRD in aging populations. In fact,
the high prevalence of AKI as well as AKI on CKD
largely mirrors underlying low nephron number
(¼CKD).9 This implies that any kind of kidney disease in
the elderly involves a variable component of underlying
irreversible nephron loss, which cannot be ﬁxed by
drugs targeting the supervening kidney disease.10 Only
drugs with beneﬁts on global mechanisms of kidney
injury show signiﬁcant renoprotective effects such as
renin-angiotensin-system blockers that reduce glomer-
ular ﬁltration load and protect from secondary podocyte
loss, glomerulosclerosis, and further nephron loss.
However, drugs acting mainly on hemodynamic
nephron injury fall short in immune-mediated kid-
ney diseases with a signiﬁcant autoimmune or in-
ﬂammatory component. Conversely, the lack of
signiﬁcant renoprotective effects of immunosuppres-
sion could indicate that autoimmunity or renal in-
ﬂammation is not the only driver of disease progression
in diseases such as chronic lupus nephritis or IgA
nephropathy.11
Disease Entities and Subentities
The deﬁnition of immune-mediated kidney diseases
remains dependent on histopathological features (e.g.,
focal segmental glomerulosclerosis, lupus nephritis,
pauci-immune, membranous, or membranoproliferative
glomerulonephritis [GN]) or traditional biomarkers
(lupus nephritis, ANCA vasculitis, diabetic nephropa-
thy). However, drug development requires an under-
standing of common pathogenetic mechanisms rather
than histopathological disease categories. Clinical trials
recruiting patients based on histopathological lesions or
biomarkers unrelated to disease mechanisms usually
fail because only a small percentage of participants
respond to the mechanism of action of the tested drug.
Hence, further subclassiﬁcation of disease entities
seems warranted. Some progress has been made for
phospholipase A2 receptorþ and phospholipase A2
receptor– membranous GN, typical and atypical
hemolytic-uremic syndrome, and C3 glomerulop-
athy.12–14 With further subclassiﬁcation of disease, one
conclusion is obvious. Immune-mediated kidney dis-
eases as individual conditions are largely rare diseases,
Figure 1. International Society of Nephrology Nexus 2016 Berlin
Symposia: Translational Immunology in Kidney Disease, 14–17 April
2016, Germany.
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for which design or implementation of traditional RCTs
is often challenging. Alternative approaches to the
generation of clinical trials may need to be considered
and will likely depend on establishing national and
international disease registries/biopsy specimen repo-
sitories of well-phenotyped and genotyped patients,
along with clinical trial networks that presently are
poorly developed in renal medicine.
Translational Interactions
A further problem is that basic and preclinical re-
searchers in the kidney domain are largely discon-
nected from the needs of the clinical domain. Cell
biology, gene editing in mice, epidemiology, and RRT-
related research are all strong ﬁelds with little inter-
action and knowledge ﬂow from one domain to the
other. To increase the translational ﬂow, it is necessary
that the domains of basic and clinical science talk to
each other and both make efforts to close the gap be-
tween them. In the following summary, we provide a
deeper analysis of current challenges and potential
solutions in target identiﬁcation and preclinical and
clinical target validation (see Figure 2).
Target Identiﬁcation
Bedside to Bench
The traditional bench-to-bedside concept is often
inefﬁcient and not cost-effective.15 Basic science has
become a complex world on its own that is largely
disconnected from the unmet needs of medical practice.
It is now evident that the traditional approach of
random basic science experiments identifying new
therapeutic targets generates very few hits that later
prove relevant in human disease in clinical trials.16,17
Too many targets are proposed by in vitro studies,
in vivo models, and immunostaining of human tissue
sections that may be involved in a disease but not
critical targets for human disease.18 For the sake of
replicability, cell lines and simple disease models of
inbred mouse strains have become standard tools of
investigation but do not recapitulate the genetic di-
versity of human populations. The high failure rates of
bench-to-bedside research together with the increasing
availability of high-throughput analytical platforms
such as genome sequencing, transcriptomics, prote-
omics, and metabolomics can reverse this traditional
approach.19 That is, translational research can now be
initiated using better characterized human phenotypes,
regardless of diversity. The development of low-
density lipoprotein-lowering proprotein convertase
subtilisin/kexin type 9 inhibitors is a good example of
this approach. The target proprotein convertase
subtilisin/kexin type 9 was found to be deﬁcient by
genome sequencing of individuals with unusually low
serum low-density lipoprotein levels.20,21 Similarly, the
identiﬁcation of APOL1 variants accounting for CKD
progression in people of African descent only occurred
when the comparison of gene proﬁles of different
ethnic groups with CKD became feasible.22,23
From bedside to bench: Targeting APOL1 over-
expression to modulate CKD progression in those of
African descent has become one of the hottest topics in
kidney research.24 Therefore, prospective phenotyping
of patients with CKD is necessary and underway, for
example, in patients with nephrotic syndrome25 or he-
reditary nephropathies (www.eurenomics.eu). Howev-
er, a coordinated (global) approach is needed to identify
subgroups of patients with similar pathological mech-
anisms of disease. This approach can no longer be
driven by kidney pathology alone but requires inte-
gration of different analytical platforms to unravel
pathological mechanisms.26 In unselected cohorts, these
platforms often only mirror already known pathways of
tissue remodeling such as inﬂammation and ﬁbrosis. It
may therefore be more promising to initiate this process
from more selected patient subgroups with unusual
genotypes and/or phenotypes that show unique fea-
tures or disease outcomes within the established disease
entities.27,28 This approach relies on study networks
with standardized data collections and biomaterial
sampling and repositories. Hence, efﬁcient target iden-
tiﬁcation may no longer be a single laboratory effort but
rather a multinational effort with a good balance be-
tween standard-operating procedures and ﬂexibility.
Another example discussed in the meeting was identi-
fying lack of or escape from CD8 T-cell exhaustion as a
cause of relapsing autoimmune disease by performing
network analysis of a patient cohort’s T-cell tran-
scriptome.29 Once identiﬁed this may serve as an early
predictor of ﬂares or as a therapeutic target to sustain
T-cell exhaustion for the maintenance of remission.
Translational flow 
in immune-mediated 
kidney disease
Global perspective
Awareness for 
lifetime nephron loss
Revise disease entities
(mechanisms not lesion)
Focus on cures, not RRT
Turn bench → bedside
into  bedside → bench
Humanize animal models
Use endpoints in animals
used in human trials
Preclinical RCTs
Trial networks needed
Post hoc analyses help
to revise patient selection
Stratify with biomarkers
No add-on designs
Replace steroid designs
Revise disease entities
(mechanisms not lesion)
Match biomarkers and
genetic testing with
drug options for 
personalized treatment
Figure 2. Strategies to improve translational ﬂow in immune-
mediated kidney diseases. RCT, randomized controlled trial; RRT,
renal replacement therapy.
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Drug Repurposing
Another strategy worth exploring for immune-mediated
kidney diseases is drug repurposing. Drugs that have
already been shown in other diseases to affect the
mechanistic pathways involved in immune-mediated
kidney diseases can be tested. This approach saves on
development time and expense, and safety proﬁles, at
least in general, are usually well known. For example,
drugs that target or deplete B and plasma cells in multiple
myeloma may be useful in autoimmune diseases with a
strong B and plasma cell contribution.30 Lupus nephritis
is particularly attractive in this context because short-
lived plasmablasts mirror systemic lupus erythemato-
sus disease activity and persistent autoimmunity in
systemic lupus erythematosus is imprinted into long-
lived plasma cells that reside in bone marrow niches
similar to myeloma cells.31 The failure of such agents in
lupus nephritis may not reﬂect mechanistic efﬁcacy, but
more likely an imbalance between the drugs’mechanism
of action and our expectations of outcomes. Depleting B
cells may be more effective at attenuating persistent
autoimmunity as opposed to rapidly resolving an acute
ﬂare of lupus nephritis. Other immune-mediated kidney
diseases that respond well to B-cell or plasma-cell-
depleting agents include membranous GN and humoral
allograft rejection.32,33 Another example of drug repur-
posing is the category of tumor necrosis factor inhibitors
that suppress necroinﬂammation and are effective in
rheumatoid arthritis and Crohn’s disease. Although a
small open label trial demonstrated the efﬁcacy of
inﬂiximab inANCAvasculitis, a larger RCT of etanercept
in granulomatosis with polyangiitis did not support this
concept.34 This outcome led to a general disregard of
tumor necrosis factor inhibitors as an option, but this
may not be appropriate as the 2 agents work differently,
and failure of etanercept when added to standard ther-
apy in granulomatosiswith polyangiitis does not exclude
a potential beneﬁt of inﬂiximab in renal vasculitis.35
Finally, leﬂunomide, a dihydroorotate dehydrogenase
inhibitor, is a potent suppressor of autoimmune arthritis
and has been repurposed for the treatment of lupus
nephritis in China, although its efﬁcacy in other ethnicities
remains to be demonstrated.36–38 Bedside-to-bench
repurposing is exempliﬁed by irinotecan, a topoisomer-
ase inhibitor developed for the treatment of colorectal
carcinoma that was found to effectively treat various
mousemodels of lupus-like immune complexGN, even at
very low doses.39
Bench-to-bedside research and drug repurposing
is captured by the broad enthusiasm for stem cell
therapies. Mesenchymal stromal cells may have stem
cell-like effects, but perhaps more importantly
have paracrine immunomodulatory effects that appear
to be relevant for promoting host immune response
modulation against donor alloantigens and facilitating a
protolerogenic environment in renal allografts.40,41 A
number of multinational research consortia are
exploring the potential of mesenchymal stromal cells in
other diseases including diabetic nephropathy.42
Adoptive transfer of ex vivo expanded or induced
regulatory T cells is also a promising therapy, now
entering clinical trials. Drug repurposing of US Food
and Drug Administration-approved drug products is
often beneﬁcial because of the previous knowledge and
experience with these drugs, which make new devel-
opment programs for the treatment of other conditions
more targeted to the appropriate patient subgroups.
Target Optimization
Novel ideas may arise from the repurposing approach. For
example, B-cell ablation with RTX was shown to have a
limited capacity to deplete tissue-based CD20þ cells
because effector cells needed for antibody-mediated
cytotoxicity may not be in these tissue compartments.
This ﬁnding initiated further efforts to reﬁne the B-cell-
targeting strategies beyond peripheral cell depletion. Be-
sides depleting B cells, inhibition of B-cell activation and
induction of inhibitory programs in B cells that interfere
withhumoral immunity are being examined in the context
of kidney disease. Several pathways of B-cell activation
(e.g., Bcl-2-associated death promoter [BAD], A
proliferation-inducing ligand [April], Bruton’s tyrosine
kinase [BTK], PI3-kinase, Lyn, nuclear factor kB, and
mammalian target of rapamycin [mTOR]) and B-cell inhi-
bition (e.g., FcgRIIb, CD22, programmed cell death protein
1 [PD-1], Src homology 2 domain–containing phosphatase
1 [SHP-1], SHIP-1, and phosphatase and tensin homolog
[PTEN]) have been identiﬁed and therapeutically
addressed. Recently, cross-linkage of CD79 was recog-
nized to induce a strong inhibitory program in B cells,
thus interfering with a large set of different B-cell acti-
vators. This approach proved to be much more potent
than RTX analogs in controlling autoimmune tissue
injury in rodents and to interfere with the development
of autoantibody production.43 Along the same lines, the
approved systemic lupus erythematosus drug belimu-
mab (anti–B-cell activating factor) is currently being
tested in a multicenter RCT to evaluate reposing it for
lupus nephritis.44
Depletion of proinﬂammatory macrophages has also
provided renoprotection in numerous animal models45
but has not yet been put forward to clinical trials.
However, the spleen tyrosine kinase inhibitor fosta-
matinib strongly inhibits macrophage activation and
is currently being trialed in IgA nephropathy
(NCT02112838), whereas cell therapy with regulatory
macrophages is being explored in living donor kidney
transplant recipients (The ONE Study). Another
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example of target optimization relates to the comple-
ment system, where the role of local extravascular
synthesis of complement components contributing to
renal transplant injury has led to site-speciﬁc targeting
with clinically ready reagents.16,46,47
Target Validation in Preclinical Disease Models
Optimizing Predictability
The concept of testing novel drugs in rodent disease
models is under increased scrutiny not only from the
public regarding animal welfare but also from the sci-
entiﬁc community and industry, because too often results
obtained in preclinical disease models have not been seen
in subsequent RCTs. Although this discrepancy is likely
to have many different explanations, it seems obvious
that the current strategy needs to be reﬁned as discussed
in detail elsewhere.2,48 Animal models used to replicate
kidney disease are often selected by the criteria of
simplicity and histopathological lesions,whichmay have
little, if anything, to do with the requirements of pre-
clinical drug testing. Closing the gap between preclinical
and clinical drug validation requires similar testing
strategies. For example, to be of predictive value pre-
clinical studies must apply the same primary and sec-
ondary endpoints as RCTs would use, such as glomerular
ﬁltration rate and urinary protein-to-creatinine ratio, an
aspect often ignored in the ﬁelds of immune complexGN,
diabetic nephropathy, or renal ﬁbrosis.2 A combination
of different experimental approaches such as consistent
data sets from knockout mice, transgenic mice, and
neutralizing compounds for a single biological target as
well as the use of multiple disease models increases pre-
dictability. For example, the alternative complement
pathwaywas found tobe activated inpatientswith active
ANCA vasculitis leading to increased C5a. Murine data
showed that genetic C5 deletion, pharmacologic C5 in-
hibition by an antibody, and myeloid-speciﬁc C5a re-
ceptor deletion protected from necrotizing GN in several
different murine disease models.49–51 Consequently, an
oral blocker of the human C5a receptor was developed,
tested in amousemodel, and is currently being evaluated
in multicenter RCTs in patients with ANCA vascu-
litis.52,53 Another clinical trial tests a human regulator
that speciﬁcally targets the complement component C3
and its role in ischemic injury of donor kidney.54Another
possibility to increase the predictability of animal models
for human disease is to conduct preclinical studies in a
multicenter RCT-like fashion with deﬁned inclusion and
exclusion criteria, blinded randomization, and central
blinded analysis similar to human trials.55,56
Mechanism Not Lesion
A major challenge is to create disease models that mimic
central pathological mechanisms of human diseases.57
The bench-to-bedside approach chooses novel targets
from basic science, tests several disease models, and
often reports only positive results, and then proclaims
that the disease model mimics the human disease.16,17
Prominent examples are models characterized by le-
sions that resemble those in “AKI,” “diabetic nephrop-
athy,” “focal segmental glomerulosclerosis,” “renal
ﬁbrosis,”without considering that the model may not at
all represent a relevant subset of patients or a clinical
scenario suitable for therapeutic intervention. The
bedside-to-bench approach starts from a target already
proven to be relevant in patients and requires animal
models that are suitable to explain the pathological
mechanisms.58,59 Comparative transcriptome analysis
may help to match human and rodent disease.60 This
approach may also include transgenic models that have
little to do with human disease but help to identify the
molecular or cellular biology behind the clinical ﬁnding.
However, target validation also requires disease models
closely similar to human disease (Table 2). This is
possible in monogenic renal disorders such as Alport
syndrome, where mice with identical mutations to those
found in humans mirror all aspects of human disease and
are suitable to reliably predict the outcome of thera-
peutic interventions.61–64 In polygenic disorders, this is
more difﬁcult to achieve. An interesting example is the
discovery of novel autoantigens in primarymembranous
GN. Several groups simultaneously described the
thrombospodin type 1 domain-containing 7A antigen
in a small subset of patients with this disease who
were not positive for antibodies to phospholipase A2
Table 2. Some rodent models of (immune-mediated) kidney with the
theoretical (and sometimes proven) capacity to predict effects in
human disease
Disease model
Glomerular disease
Monogenetic models of Alport nephropathy, primary FSGS, C3 nephropathy
Anti-GBM disease based on immunization with a3(IV)NC1 antigen
Polygenic models of lupus nephritis, IgAN, and type 2 diabetic nephropathy
Transplanting wild-type bone marrow into Mpo–/– mice immunized with MPO.
Experimental autoimmune vasculitis, based on immunization with MPO
THSD7A-related membranous GN, Heymann nephritis
Tubulointerstitial disease
Monogenetic models of polycystic kidney disease, primary hyperoxaluria, and other
monogenetic tubulolar disorders (UMOD, etc.)
Infective pyelonephritis
Some kidney allograft rejection models
Polymicrobial sepsis-induced AKI models
Toxin-induced models of AKI/CKD that exist in humans (rhabdomyolysis, CyA,
aristolochic acid, oxalate, cisplatin, etc.)
Contrast media-induced AKI
Secondary tubular injury in glomerular models
Mice with humanized immune system
AKI, acute kidney injury; CKD, chronic kidney disease; FSGS, focal segmental glomer-
ulosclerosis; GBM, glomerular basement membrane; GN, glomerulonephritis; IgAN, IgA
nephropathy; MPO, myeloperoxidase; NC1, noncollagenous domain 1; THSD7A,
thrombospondin type 1 domain-containing 7A; UMOD, uromodulin.
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receptor.65 Injection of human anti-thrombospodin type
1 domain-containing 7A autoantibodies into mice can
induce features of membranous GN.65 However, this
passive approach ignores the elements of adaptive im-
mune mechanisms of membranous GN that operate
outside the kidney.66 The same applies to crescentic GN
induced by glomerular basementmembrane antisera, but
autologous models of anti-GBM disease now exist and it
remains to be explored if this is also feasible for throm-
bospodin type 1 domain-containing 7A-related GN.67 A
more accurate model of anti-glomerular basement mem-
brane disease can be induced in the rat, in which im-
munization with a3 (IV) noncollagenous domain 1 (the
“Goodpasture antigen”) leads to severe crescentic
nephritis similar to that inpatients.68 Thismodel has been
of value in investigating novel therapeutic approaches,
for example, the inhibition of spleen tyrosine kinase.69
Generatingmicewith a human immune system is another
option to better mimic human immune targets in ro-
dents.70 For example, such mice were used to assess the
in vivo efﬁcacy of small molecule antagonists against
human CC chemokine receptor-2.71 This approach was
proven to be predictive as a subsequent RCTdocumented
in vivo efﬁcacy of the lead compound in patients with
type 2 diabetic nephropathy.72
Target Validation in Clinical Trials
Performing RCTs in immune-mediated kidney dis-
eases is challenging for many different reasons. One
challenge is trial costs because relevant effect size, for
example, on CKD progression can only be demon-
strated in trials lasting years. This generates a hurdle
difﬁcult to bypass for academic investigators and even
multinational consortia, if not funded by generous
public bodies or private foundations. However, Na-
tional Institutes of Health’s funding for kidney
research is disproportionately low compared with other
less common disease entities.
Orphan Diseases
Immune-mediated kidney diseases are mostly rare dis-
eases; hence, single center studies, albeit frequently
performed, are not sufﬁciently powered to reach reliable
conclusions.73,74 Some diseases are suitable to test new
interventions in trials with few patients. For example,
cross-over designs or matched-cohort studies are able to
considerably reduce the numbers of patients needed to
gain evidence. The extreme of this approach is the “n¼ 1
trial” that sequentially assesses standard and experi-
mental treatments in an individual patient.75 However,
the latter approach is limited to diseases that demonstrate
rapid and clear short-term responses to an effective
treatment. For example, in thrombocytic thrombocyto-
penic purpura, plasma exchange could be easily tested
versus plasma infusion in a single patient using platelet
count recovery as a short-term readout because the
readout of response to treatment is rapid and robust.76
Testing less robust treatment effects is also possible in a
step-up trial design, where a single or a small number of
patients are treatedwith an innovative drug. Beforemore
patients are exposed to the drug, the ﬁrst patients are
extensively phenotyped for drug exposure, biomarkers
of mechanism of action, and treatment outcome to
eventually adjust drug dosing and timing of the inter-
vention. In this stepwise, or adaptive design, approach,
optimizing these parameters is possible before moving to
a larger or a controlled trial.77,78 In rare diseases, control
groups in trialsmaynot evenbe needed ormaybe simply
unethical.78 Historical controls might be used instead.63
However, these approaches can hardly be used in GN
and most other forms of immune-mediated kidney dis-
ease where such a short-term readout parameter is not
available. To solve this problem, clinical trial networks
need to be set up to bring together sufﬁcient numbers of
patients. Where such trial networks efﬁciently collabo-
rate, for example, in the European Vasculitis Study
Group (http://www.vasculitis.org/), the results of the
numerous sequentially performed trials were able to set
the current standards for patient management and the
assessment of newer therapies, such as RTX.79 Recently,
a network has been set up for lupus nephritis called the
Lupus Nephritis Trial Network (http://lupusnephritis.
org/). Such networks are also needed for other forms of
GN to facilitate efﬁcient multicenter RCTs.
Stratifying for Pathological Mechanism
Another challenge for RCTs is patient stratiﬁcation for
treatments with highly speciﬁc mechanisms of action.
Current disease categories are often based on histo-
pathological lesions and biomarkers, but individual
patients have very diverse underlying pathological
mechanisms.80,81 Identifying subgroups of patients with
similar pathogenic mechanisms that are related to the
presumptivemechanism of action of the innovative drug
could be an important step forward in evaluating novel
treatments that would otherwise fail to show signiﬁcant
treatment beneﬁts in unselected patient cohorts. For
example, such patient stratiﬁcation can be achieved by
genetic testing of patients with idiopathic nephrotic
syndrome, as to exclude those with a genetic podocyt-
opathy that would not beneﬁt from immunosuppressive
treatments.82 In lupus nephritis, a more sophisticated
analysis of the blood leukocyte or even the kidney
transcriptome may allow stratiﬁcation of patient sub-
populations that can be tested for unique pathological
mechanisms and outcomes.83 Selecting speciﬁc treat-
ments for certain patient subgroups would approach
the innovative precision medicine concept currently
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being established in the ﬁeld of oncology. However, this
still creates a challenge as subgroups in a rare disease
might be so small as to prohibit an adequately powered
trial or even arouse commercial interest.
Stratifying for Ethnicity?
Race and ethnicity affect the risk of CKD progression in
many immune-mediated kidney diseases. Different
outcomes in ethnic groups are now proven to be driven
by genetic factors such as APOL1, which can affect the
outcome of trials independent of drug efﬁcacy.84
Ethnicity also inﬂuences drug dosing because drug
metabolism clearly differs among ethnic groups, which
affects drug efﬁcacy and toxicity in trials with a ﬁxed
dosing regimen.85 Failing to take into account ethnicity-
related heterogeneity of CKD progression and drug
metabolism can drastically compromise the assumptions
underlying statistical power and group size calculations
in global multicenter RCTs or of regional RCTs in
countries with multiethnic populations.86 Acknowl-
edging this problem implies that the results of clinical
trials may be limited to certain ethnic groups, until
proven otherwise. For example, several trials have tested
leﬂunomide, mycophenolate mofetil, or mycophenolate
mofetil þ tacrolimus only in cohorts of Chinese patients
with lupus nephritis.38,87,88 The Caucasian Euro Lupus
trials are another example,89 although the low-dose
cyclophosphamide (CTX) dose-restricted Euro lupus
regimen has recently been proven to be noninferior to
high-dose CTX also in African Americans and Hispanics
participating in the Abatacept and Cyclophosphamide
Combination Efﬁcacy and Safety Study.90,91
Add-on Design
Study design is much inﬂuenced by the disease being
treated, standard of care for that disease, the antici-
pated effects of the investigational therapy, and ethics
of giving clinical treatment versus placebo. For
example, a number of studies of lupus nephritis con-
ducted in the past used the add-on treatment design
(standard of care plus placebo vs. standard of care plus
investigational therapy) and sought statistical superi-
ority. However, this design appeared most yielding
when the magnitude of effect of the background
treatment was smaller than that of the investigational
treatment, best exempliﬁed perhaps by the addition of
a tumor necrosis factor-alpha inhibitor to methotrexate
monotherapy in rheumatoid arthritis. A similar design
in lupus nephritis may be less yielding for statistical
demonstration of drug effect because the large
doses of background steroids may mask the effect of
adding on a new therapy, particularly if that therapy is
of modest beneﬁt. But as long as standard therapy
consists of broadly immunosuppressant drugs, more
selective immunosuppressant drugs with overlapping
mechanisms of actions are unlikely to improve response
rates.2 A study designed as a noninferiority comparison
with the new drug replacing the steroid component of
the standard of care might be more useful. Replacing
steroids would address an important unmet medical
need in lupus nephritis. Such a design, however,
should be chosen carefully to ensure that patients
receive the appropriate care that is effective in treating
lupus nephritis ﬂare regardless of the selected study
design and treatment agents. In addition, non-
inferiority designs require robust evidence character-
izing the selected noninferiority margin. A prospective
trial using RTX in addition to mycophenolate allowed
early withdrawal of steroids.92 Such alternative trial
designs need to be further explored in the ﬁeld of
immune-mediated kidney diseases.
Study Endpoints
The right study endpoints for RCTs remain a matter of
debate.73,74 Nephron number would be a sensitive
surrogate marker for CKD progression but is unfortu-
nately not yet available.9 Currently, serum creatinine,
estimated glomerular ﬁltration rate, and proteinuria are
used as trial endpoints for most forms of kidney disease
although endpoints such as steroid dose, time to ﬂare,
or patient-oriented outcomes such as quality of life
would also be meaningful.93 In addition, serum creat-
inine and proteinuria are not directly linked to the
mechanism of action of immunomodulatory drugs and
require years to reveal drug efﬁcacy in chronic forms of
GN. Kidney biopsy is the current gold standard to
determine resolution versus ongoing intrarenal
inﬂammation and should be ideally considered as
mandatory for trial endpoints; if a negative impact on
patient recruitment is an overwhelming concern, a
repeat kidney biopsy should at least be an optional
study endpoint for most trials. Post hoc analyses of
previous trial data sets are a useful tool to reﬁne future
trial strategies in terms of minimizing variability and
increasing trial power. Therefore, it is important that
trial data become accessible to researchers and data
sharing becomes a common standard. Collaborative
efforts by the National Kidney Foundation and the US
Food and Drug Administration in 2012 and a subse-
quent collaborative initiative together with the Lupus
Nephritis Trial Network deﬁned surrogate parameters
for CKD progression in general and in lupus
nephritis.94 In addition, Lupus Nephritis Trial Network
members sharing their data from the Eurolupus,
Mycophenolate Mofetil Versus Azathioprine for
Maintenance Therapy of Lupus Nephritis (MAINTAIN)
and Aspreva Lupus Management Study (ALMS) trials
were able to reassess the predictive value of proteinuria
response to induction and maintenance therapy as a
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surrogate for CKD progression.95 Similar attempts were
made on “failed” diabetes trials such as ONgoing Tel-
misartan Alone and in combination with Ramipril
Global Endpoint Trial (ONTARGET), SUN, treat-to-
target (TREAT), Aliskiren Trial in Type 2 Diabetes
Using Cardiovascular and Renal Disease Endpoints
(ALTITUDE), Veterans Affairs Nephropathy in Dia-
betes (VA-Nephron), Bardoxolone Methyl Evaluation
in Patients With Chronic Kidney Disease and Type 2
Diabetes (BEACON), A Study of Cardiovascular Events
iN Diabetes (ASCEND), where post hoc analysis retrieved
important information to work out better composite
endpoints that will help to minimize risk and maximize
effect in future trials. Finally, induction of remission is
not the only useful study endpoint. In relapsing dis-
eases such as renal vasculitis, nephrotic syndrome, or
lupus nephritis, monitoring early predictors of ﬂares
and comparing time to ﬂare between treatment arms
with different maintenance therapies should be
considered as useful and relevant endpoints.
Cost-effectiveness
Controlling disease is the goal but at what cost? Many
new drugs are costly and have only a modest effect
size. By contrast, to see a strong effect size in kidney
disease usually requires long and very costly trials. A
careful analysis of the number-needed-to-treat, short-
term, and long-term adverse events, impact on quality
of life as well as direct and indirect costs will have a
strong impact on whether a drug passes into routine
clinical practice. For example, steroid treatment only
marginally improved estimated glomerular ﬁltration
rate decline in IgA nephropathy but was associated
with toxicity.11 Also drug costs affect decision making.
For example, oral CTX involves drug costs of 72 Euros,
whereas treatment with RTX, which was noninferior
but not superior to CTX for the induction therapy of
ANCA vasculitis, involves 17,500 Euros in drug costs
and around 9000 Euros in hospitalization costs in
France. These costs do not take into account routine lab
monitoring for CTX, and cost modeling remains com-
plex. RTX in granulomatosis with polyangiitis and
microscopic polyangiitis was formally evaluated by the
National Institute for Health and Care Excellence in the
UK and guidance was issued for RTX use in 2014 with
speciﬁc recommendations (https://www.nice.org.uk/
guidance/TA308). Thus, once approved, novel drugs
need to be carefully evaluated for cost-effective use.
Clever drug development requires wise predictions on
the result of this process as early as possible. Finally, we
should not forget that the most cost-effective treatment
in immune-mediated kidney diseases may sometimes
simply be a rigorous conservative treatment of CKD as
previously shown in 12 years’ follow-up of a single case
with lupus nephritis or more recently for patients with
IgA nephropathy.11,96
Conclusion
Many challenges compromise the translational ﬂow of
new therapies from bench to bedside in immune-
mediated kidney diseases. Identifying the problems is
the ﬁrst step toward improvement. Further discussions
and coordinated actions (Table 3) endorsed by national
or international societies, industry, funding organiza-
tions, and regulatory bodies are needed to solve the
pending issues. A more stringent focus on human
rather than mouse disease with well-characterized hu-
man disease phenotypes ranging from relatively rare
monogenic strong phenotypes to polygenic common
phenotypes will stratify the patients with causative
pathogenic mechanisms rather than only the histo-
pathological pattern. This requires more efforts in hu-
man biomarker research and the bedside-to-bench
research approach. Once clariﬁed the clever design
of shorter trials with robust endpoints for CKD pro-
gression is needed to bypass the traditional add-on
design of immunomodulatory drugs that have
Table 3. Berlin roadmap
 Increase awareness for nephron loss along lifetime with risk for end-stage renal disease
(ESRD) at advanced age and add-on nephron losses with any kidney disease, implying
mid-age ESRD.
 Support initiatives that shift ﬁnancial incentives from renal replacement therapy to
prevention of ESRD to promote cost-effective use of kidney disease health care budgets.
 Raise interest in young doctors for nephrology by transforming the subject from renal
replacement and maintenance orientated into a curative discipline.
 Support initiatives that try to overcome the disconnection of basic kidney research
and clinical research. Support clinical scientists track and endorse bedside-to-bench
research.
 Revise current preclinical animal testing. Endorse humanized animal models of kidney
disease. Deﬁne models by the involved pathomechanisms not by histopathological
lesions. To increase predictability of preclinical animal studies, these studies must be
conducted using same protocols and endpoint analysis as performed in humans.
 Personalized and precision medicine in kidney disease requires stratifying patients
within current disease entities for involved pathomechanisms. This requires suitable
biomarkers and potentially genetic testing to match the right patients with available
treatment options.
 Use this approach in future randomized controlled trials to avoid diluting drug effects by
maintaining too many obvious nonresponders within the trial. This is also not done in
clinical practice. Use post hoc analysis data from previous trials to deﬁne the right
patient subgroups.
 Trials in immune-mediated kidney diseases may not necessarily be set up as superiority
trials. Replacing steroids may be a better strategy, especially for drugs with overlapping
mechanism of action to steroid treatment.
 Some renal diseases qualify for trial designs other than randomized controlled trial
(RCT). Several alternative options exist including cross-over designs and even n ¼ 1
trials.
 As immune-mediated kidney diseases are mostly rare diseases, forming multinational
trial networks will be essential to conduct meaningful RCTs.
 Endorse national or international registries and open access databases on the
epidemiology, phenotype, and renal care of kidney disease patients.
 Endorse studies on race/ethnicity differences of disease phenotypes, pharmacogenetics,
and treatment outcomes.
 The genetic basis of adult kidney disease needs to be explored.
 A quantitative biomarker of nephron number is needed to deﬁne nephron loss from the
number present at birth, during disease or as a structural comparative endpoint for
clinical trials.
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redundant mechanisms of action. The unmet medical
need of kidney patients and the availability of well-
characterized patient cohorts, modern bioinformatics,
and big data analysis together with latest drug devel-
opment tools also require an update of preclinical and
clinical target validation to eventually come up with
more innovative cures for our patients with immune-
mediated kidney disease.
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